» Articles » PMID: 17000035

Recombinant M. Smegmatis Vaccine Targeted Delivering IL-12/GLS into Macrophages Can Induce Specific Cellular Immunity Against M. Tuberculosis in BALB/c Mice

Overview
Journal Vaccine
Date 2006 Sep 27
PMID 17000035
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, we constructed a viable therapeutic vaccine of recombinant M. smegmatis mediated IL-12/GLS (granulysin) gene transfer into murine macrophages to exert the immunotherapy effects on the Mycobacterium tuberculosis infection. We tested this recombinant therapeutic vaccine in an in vivo study to determine its capability of stimulating host specific immune responses against M. tuberculosis. BALB/c mice intranasally immunized with the therapeutic vaccine developed an efficient Th1 protective immune response against M. tuberculosis which was equal to that of the BCG strain. Inoculation intranasally with this viable vaccine induced high level of serum IFN-gamma, IL-12 and IgG2a. The viable vaccine was capable of inducing purified protein derivative (PPD) antigen-specific splenocytes proliferation and IFN-gamma production from T cells in spleens of the immunized mice. In addition, intranasally inoculation with the viable vaccine can induce PPD antigen-specific sIgA production in the broncho-alveolar lavage fluid (BALF) of the immunized mice. No change of IL-4 level was found in all groups. The therapeutic mechanism of this viable vaccine against M. tuberculosis infection observed here appeared to be a result of the specific Th1 immune response activated by mycobacterium antigen from M. smegmatis and the expression of sIL-12/GLS in alveolar macrophages via the M. smegmatis-mediated gene transfer method. This research demonstrates that the therapeutic gene can be introduced into a host by viable mycobacteria works to induce the host specific immune response against M. tuberculosis infection in vivo. Since this therapeutic vaccine can strongly induce specific Th1 responses against M. tuberculosis in BALB/c mice and has no obviously harmfulness to the host simultaneously, the recombinant vaccine might be a potential candidate therapeutic vaccine against tuberculosis.

Citing Articles

, a Promising Vaccine Vector for Preventing TB and Other Diseases: Vaccinomics Insights and Applications.

Xie W, Wang L, Luo D, Soni V, Rosenn E, Wang Z Vaccines (Basel). 2023; 11(8).

PMID: 37631870 PMC: 10459588. DOI: 10.3390/vaccines11081302.


Recombinant coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Liu W, Xu Y, Shen H, Yan J, Yang E, Wang H Exp Ther Med. 2017; 13(5):2339-2347.

PMID: 28565847 PMC: 5443280. DOI: 10.3892/etm.2017.4273.


Inhalation of recombinant adenovirus expressing granulysin protects mice infected with Mycobacterium tuberculosis.

Ma J, Lu J, Huang H, Teng X, Tian M, Yu Q Gene Ther. 2015; 22(12):968-76.

PMID: 26181627 DOI: 10.1038/gt.2015.73.


The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.

Lee H, Kim B, Kim B, Kook Y, Kim B PLoS One. 2015; 10(3):e0122897.

PMID: 25822634 PMC: 4378964. DOI: 10.1371/journal.pone.0122897.


Prime-boost with Mycobacterium smegmatis recombinant vaccine improves protection in mice infected with Mycobacterium tuberculosis.

Junqueira-Kipnis A, de Oliveira F, Trentini M, Tiwari S, Chen B, Resende D PLoS One. 2013; 8(11):e78639.

PMID: 24250805 PMC: 3826754. DOI: 10.1371/journal.pone.0078639.